| ID Source | ID |
|---|---|
| PubMed CID | 6419954 |
| CHEMBL ID | 1723241 |
| CHEBI ID | 63858 |
| MeSH ID | M0329612 |
| Synonym |
|---|
| MLS002154172 |
| smr001233470 |
| sulfacetamidum natricum |
| sulfacetamide sodic hydrate |
| PRESTWICK_427 |
| 6209-17-2 |
| NCGC00017061-01 |
| cas-6209-17-2 |
| nsc-625324 |
| sulfacetamide sodium salt monohydrate |
| D00871 |
| klaron (tn) |
| cetamide (tn) |
| bleph (tn) |
| sulfacetamide sodium (usp) |
| sulfacetamide sodium monohydrate |
| n1-acetylsulfanilamide sodium monohydrate |
| bleph-30 |
| acetamide, n-((4-aminophenyl)sulfonyl)-, monosodium salt, monohydrate |
| sulfair forte |
| sulamyd sodium monohydrate |
| n-sulfanilylacetamide monosodium salt monohydrate |
| sodium sulfacetamide , |
| ocusulf-30 |
| sodium n-sulfanilylacetamide monohydrate |
| sulten-10 |
| sulfair 10 |
| ocusulf-10 |
| sulf-15 |
| acetamide, n-sulfanilyl-, monosodium salt, monohydrate |
| sulfair-15 |
| NCGC00017061-02 |
| flammazine |
| sulfacetamide sodium salt monohydrate, >=98.0% (dried material, t) |
| sodium acetyl[(4-aminophenyl)sulfonyl]azanide hydrate |
| STK023979 |
| AKOS000489082 |
| HMS1568C09 |
| sumaxin |
| sulfatol |
| topisulf |
| ocusulf |
| claris |
| rosula |
| cerisa |
| sulfacetamide sodium [usp] |
| sulfacel |
| zencia wash |
| prascion |
| unii-4nrt660kjq |
| plexion |
| bleph |
| HMS2095C09 |
| n-[(4-aminophenyl)sulfonyl]acetamide, oxamethane, sodium salt |
| HMS2231L18 |
| S4750 |
| AKOS005379705 |
| sulfacetamide sodium salt hydrate |
| 4nrt660kjq , |
| rosaderm |
| sodium acetyl[(4-aminophenyl)sulfonyl]azanide--water (1/1) |
| CHEBI:63858 , |
| sulfacetamide sodium hydrate |
| sulfacetamide sodium component of isopto cetapred |
| sulfacetamide sodium [ep impurity] |
| sulfacetamide sodium [vandf] |
| metimyd component sulfacetamide sodium |
| sulphrin component sulfacetamide sodium |
| sulfacetamide sodium component of sulphrin |
| fml-s component sulfacetamide sodium |
| sulfacetamide sodium [ii] |
| sulfacetamide sodium [ep monograph] |
| sulster component sulfacetamide sodium |
| sulfacetamide sodium component of fml-s |
| sulfacetamide sodium salt monohydrate [mi] |
| predsulfair component sulfacetamide sodium |
| sulfacetamidum natricum [who-ip latin] |
| isopto cetapred component sulfacetamide sodium |
| sulfacetamide sodium [who-ip] |
| cetapred component sulfacetamide sodium |
| sulfacetamide sodium component of sulster |
| sulfacetamide sodium [orange book] |
| sulfacetamide sodium [usp monograph] |
| sulfacetamide sodium [mart.] |
| sulfacetamide sodium component of metimyd |
| sulfacetamide sodium component of blephamide s.o.p. |
| blephamide component sulfacetamide sodium |
| predamide component sulfacetamide sodium |
| blephamide s.o.p. component sulfacetamide sodium |
| sulfacetamide sodium component of predsulfair |
| sulfacetamide sodium component of predamide |
| sulfacetamide sodium [usp-rs] |
| sulfacetamide sodium component of cetapred |
| sulfacetamide sodium component of blephamide |
| HMS3372D13 |
| sodium sulfacetamide, anhydrous |
| CCG-220014 |
| CHEMBL1723241 |
| HY-B0888 |
| DTXSID50211129 , |
| mfcd00149555 |
| sr-01000842154 |
| SR-01000842154-2 |
| sulfacetamide sodium, united states pharmacopeia (usp) reference standard |
| HMS3712C09 |
| sodium acetyl((4-aminophenyl)sulfonyl)amide hydrate |
| s4750 sulfacetamide sodium salt hydr |
| sodium acetyl(4-aminophenylsulfonyl)amide hydrate |
| Q27132864 |
| sodium;acetyl-(4-aminophenyl)sulfonylazanide;hydrate |
| AS-81746 |
| sulfacetamidesodiummonohydrate |
| sodium acetyl[(4-aminophenyl)sulfonyl]amide hydrate |
| SY076524 |
| sulfacetamide sodium (ep impurity) |
| ovace |
| sodium acetyl((4-aminophenyl)sulfonyl)azanide--water (1/1) |
| sodium acetyl((4-aminophenyl)sulfonyl)azanide |
| ovaceplusplus |
| plexion ns |
| sulfacetamide sodium (ii) |
| exact-rx sodium sulfacetamide wash 10% |
| dtxcid00133620 |
| sulfacetamide sodium (usp-rs) |
| ovaceplus |
| ovace plus |
| sodium sulfacetamidewash |
| sodium sulfacetamide wash 10% |
| sulfacetamide sodium (usp monograph) |
| sulfacetamide sodium (ep monograph) |
| sulfacetamide sodium (mart.) |
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antiinfective agent | A substance used in the prophylaxis or therapy of infectious diseases. |
| EC 2.5.1.15 (dihydropteroate synthase) inhibitor | An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organic sodium salt | |
| hydrate | An addition compound that contains water in weak chemical combination with another compound. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| IDH1 | Homo sapiens (human) | Potency | 6.5131 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 0.3981 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||